Breaking News: Innocare’s Orelabrutinib Makes History as China’s First and Only Approved BTK Inhibitor for Treating R/R MZL
Exciting News in the Biopharmaceutical Industry Beijing–InnoCare Pharma (HKEX: 09969; SSE: 688428) has made a groundbreaking announcement today, revealing that its BTK inhibitor orelabrutinib has been granted approval by the China National Medical Products Administration (NMPA) for the treatment of patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL). This marks a significant milestone as orelabrutinib…